IL96549A - Production of biologically active transforming growth factor type B-like protein or salts thereof - Google Patents

Production of biologically active transforming growth factor type B-like protein or salts thereof

Info

Publication number
IL96549A
IL96549A IL9654990A IL9654990A IL96549A IL 96549 A IL96549 A IL 96549A IL 9654990 A IL9654990 A IL 9654990A IL 9654990 A IL9654990 A IL 9654990A IL 96549 A IL96549 A IL 96549A
Authority
IL
Israel
Prior art keywords
production
biologically active
protein
salts
growth factor
Prior art date
Application number
IL9654990A
Other languages
English (en)
Other versions
IL96549A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL96549A0 publication Critical patent/IL96549A0/xx
Publication of IL96549A publication Critical patent/IL96549A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL9654990A 1989-12-06 1990-12-05 Production of biologically active transforming growth factor type B-like protein or salts thereof IL96549A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927546A GB8927546D0 (en) 1989-12-06 1989-12-06 Process for the production of biologically active tgf-beta

Publications (2)

Publication Number Publication Date
IL96549A0 IL96549A0 (en) 1991-09-16
IL96549A true IL96549A (en) 2000-10-31

Family

ID=10667491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9654990A IL96549A (en) 1989-12-06 1990-12-05 Production of biologically active transforming growth factor type B-like protein or salts thereof

Country Status (23)

Country Link
US (2) US5650494A (fr)
EP (2) EP0433225B1 (fr)
JP (1) JP3048061B2 (fr)
KR (1) KR100203230B1 (fr)
AT (1) ATE178616T1 (fr)
AU (1) AU638075B2 (fr)
CA (1) CA2031430C (fr)
DE (1) DE69033040T2 (fr)
DK (1) DK0433225T3 (fr)
ES (1) ES2132066T3 (fr)
FI (1) FI103278B (fr)
GB (1) GB8927546D0 (fr)
GR (1) GR3030703T3 (fr)
HU (1) HU218144B (fr)
IE (2) IE904386A1 (fr)
IL (1) IL96549A (fr)
MX (1) MX172600B (fr)
NO (1) NO301768B1 (fr)
NZ (1) NZ236333A (fr)
PH (1) PH31649A (fr)
PT (1) PT96068B (fr)
SG (1) SG52690A1 (fr)
ZA (1) ZA909762B (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
EP0547102B1 (fr) * 1990-09-05 1998-07-08 Southern Cross Biotech Pty.Ltd. Solubilisation de proteines sous des formes actives
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
EP0612348B1 (fr) 1991-11-04 2003-04-23 Genetics Institute, LLC Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
EP0678102A1 (fr) * 1993-01-08 1995-10-25 The Upjohn Company Procede de purification et de repliement de la glycoproteine fg du virus syncytial respiratoire humain
AU6794594A (en) 1993-04-30 1994-11-21 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta )
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
AU7846894A (en) * 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
CA2176942C (fr) * 1993-12-07 2011-11-01 Anthony J. Celeste Bmp-12, bmp-13 et compositions de celles-ci pour l'induction de tendons
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
EP0804461A1 (fr) * 1994-07-25 1997-11-05 Novartis AG Procede de repliement de proteines telles que l'hirudine ou le facteur de croissance epidermique de recombinaison
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
ATE325131T1 (de) 1995-04-19 2006-06-15 Bioph Biotech Entw Pharm Gmbh Neues protein und verfahren zu dessen herstellung
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6040431A (en) 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
JP4019432B2 (ja) * 1995-12-21 2007-12-12 味の素株式会社 ヒトアクチビンａのリフォールディング方法
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
CA2244228A1 (fr) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Procedes et composition de production d'analogues morphogenes
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
EP0896825B1 (fr) 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition et dispositif pour la réparation de cartilage in vivo comprenant des nanocapsules avec des facteurs ostéoinductifs et/ou chondroinductifs
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
EP1659178B1 (fr) * 1998-02-05 2010-03-31 GlaxoSmithKline Biologicals SA Procédé de purification ou de préparation de la proteine MAGE
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
CA2358609A1 (fr) * 1999-01-07 2000-07-13 Takeda Chemical Industries, Ltd. Procede de production de proteines activees
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
CA2643162C (fr) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Systeme et procede d'identification et de sequencage de polymeres, et d'analyse de leur composition par comparaison des proprietes
DE19944626A1 (de) * 1999-09-17 2001-03-22 Knoell Hans Forschung Ev Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
CA2402160C (fr) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii et ses utilisations
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
JP4911865B2 (ja) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
MXPA03007563A (es) 2001-02-23 2003-12-11 Immunex Corp Recuperacion incrementada de proteinas activas.
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7226587B2 (en) * 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1432431B1 (fr) 2001-10-04 2017-05-10 Genetics Institute LLC Procedes et compositions permettant de moduler l'activite de l'interleukine-21
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
CA2475235C (fr) * 2002-02-05 2013-04-30 Geymonat S.P.A. Procede de production d'un facteur de croissance placentaire recombinant
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
MXPA05001734A (es) * 2002-08-13 2005-07-22 Wyeth Corp Peptidos como excipientes de solubilizacion para proteinas del factor 8 de crecimiento de transformacion.
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7074412B2 (en) 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
CA2522364C (fr) 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Neublastine a conjugaison polymere glycosylee
ATE357244T1 (de) 2003-09-12 2007-04-15 Wyeth Corp Injizierbare feste calciumphosphat-stäbe zur abgabe von osteogenen proteinen
ES2403357T3 (es) 2003-12-11 2013-05-17 Isto Technologies Inc. Sistema de cartílago particulado
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
BRPI0514409A (pt) 2004-08-19 2008-06-10 Biogen Idec Inc redobra de proteìnas da famìlia de fator de crescimento transformante beta
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
GT200600065A (es) 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
CN101511858A (zh) * 2005-07-25 2009-08-19 特鲁比昂药品公司 用于蛋白质解聚的组合物和方法
GB0516204D0 (en) * 2005-08-06 2005-09-14 Riotech Pharmaceuticals Ltd Methods
EP1916964A4 (fr) 2005-08-26 2015-11-04 Zimmer Inc Implants et procedes pour la reparation, le remplacement et le traitement de maladies articulaires
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (fr) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compositions et procedes d'administration de proteines de la famille des ligands gdnf
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
AU2007272412B2 (en) * 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
PL2078071T3 (pl) 2006-11-08 2015-07-31 Wyeth Llc Racjonalnie opracowane pożywki do hodowli komórek
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
WO2008128075A1 (fr) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions et procédés de réparation de tissu
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009023562A2 (fr) 2007-08-09 2009-02-19 Wyeth Utilisation de la perfusion pour améliorer la production d'une culture cellulaire en mode semi-continu dans des bioréacteurs
WO2009029656A1 (fr) 2007-08-27 2009-03-05 Auxagen, Inc. Procédés d'inhibition de tgf-β
CN102159219B (zh) 2008-09-16 2015-06-24 圣路易斯大学 提高转化生长因子-β信号发送的方法
US8494140B2 (en) * 2008-10-30 2013-07-23 Centurylink Intellectual Property Llc System and method for voice activated provisioning of telecommunication services
EP2350130B1 (fr) 2008-10-31 2018-10-03 Wyeth LLC Purification de protéines acides à l aide d une chromatographie sur hydroxyapatite en céramique
AU2010270986B2 (en) * 2009-06-22 2014-05-22 Amgen Inc. Refolding proteins using a chemically controlled redox state
EP2445924B2 (fr) 2009-06-25 2023-12-13 Amgen Inc. Procédés de purification par capture de protéines exprimées dans un système non mammifère
KR100991203B1 (ko) 2010-05-10 2010-11-01 심영복 골형성 단백질의 정제 방법
WO2012029148A1 (fr) 2010-09-01 2012-03-08 株式会社オステオファーマ Préparation cryodesséchée de protéine morphogénétique osseuse humaine recombinante 2
CN107049910A (zh) * 2012-02-10 2017-08-18 株式会社加帕尼克 干细胞培养上清的生发育发用途、化妆品或皮肤形成促进剂以及蛋白质的离子导入方法
DK2879691T3 (da) 2012-08-06 2019-06-11 Biogen Ma Inc Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CA3048735A1 (fr) 2016-12-30 2018-07-05 Biogend Therapeutics Co., Ltd. Polypeptides recombinants, compositions et procedes associes

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811970B (en) * 1980-03-27 1982-11-24 Lilly Co Eli Process for producing an insulin
GR79124B (fr) * 1982-12-22 1984-10-02 Genentech Inc
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
WO1984004924A1 (fr) * 1983-06-03 1984-12-20 Us Commerce Facteur de croissance purifie de transformation du type beta derive de thrombocytes et de placentas humains
ATE85080T1 (de) * 1984-02-17 1993-02-15 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) * 1985-02-22 1988-03-15 Monsanto Company Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
EP0208539A3 (fr) * 1985-07-11 1988-08-03 Repligen Corporation Protéines pliantes liées par pont disulfuré en croix
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
WO1988003807A2 (fr) * 1986-11-17 1988-06-02 Sandoz Ag Production et emploi d'un nouveau facteur suppresseur de cellules-t
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0368857B1 (fr) * 1987-05-11 1997-08-06 Chiron Corporation Procede de recuperation, a partir de microorganismes, d'interleukine-2 recombinante, purifiee, oxydee et renaturee
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5144006A (en) * 1991-06-13 1992-09-01 The Rockefeller University Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors

Also Published As

Publication number Publication date
NO905264D0 (no) 1990-12-05
GB8927546D0 (en) 1990-02-07
SG52690A1 (en) 1998-09-28
AU6701890A (en) 1991-06-13
EP0433225A1 (fr) 1991-06-19
IL96549A0 (en) 1991-09-16
GR3030703T3 (en) 1999-11-30
CA2031430A1 (fr) 1991-06-07
PT96068A (pt) 1991-09-30
PH31649A (en) 1999-01-12
NO301768B1 (no) 1997-12-08
FI905956A0 (fi) 1990-12-03
HUT56880A (en) 1991-10-28
NO905264L (no) 1991-06-07
ZA909762B (en) 1991-08-28
CA2031430C (fr) 2003-05-27
HU908084D0 (en) 1991-06-28
IE990992A1 (en) 2000-12-13
KR910012240A (ko) 1991-08-07
JP3048061B2 (ja) 2000-06-05
DE69033040D1 (de) 1999-05-12
FI905956A (fi) 1991-06-07
JPH03191791A (ja) 1991-08-21
KR100203230B1 (ko) 1999-06-15
MX172600B (es) 1994-01-03
DK0433225T3 (da) 1999-10-25
FI103278B1 (fi) 1999-05-31
EP0891985A1 (fr) 1999-01-20
IE904386A1 (en) 1991-06-19
DE69033040T2 (de) 1999-09-09
AU638075B2 (en) 1993-06-17
US5922846A (en) 1999-07-13
PT96068B (pt) 1998-02-27
ES2132066T3 (es) 1999-08-16
FI103278B (fi) 1999-05-31
HU218144B (hu) 2000-06-28
EP0433225B1 (fr) 1999-04-07
US5650494A (en) 1997-07-22
NZ236333A (en) 1992-03-26
ATE178616T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
IL96549A (en) Production of biologically active transforming growth factor type B-like protein or salts thereof
DE59005250D1 (de) Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen.
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
ATE76753T1 (de) Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
IL91152A0 (en) Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
DE3784308D1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
IL85031A (en) Lyophilized aspoxicillin preparation and its manufacture
EP0304897A3 (fr) Procédé d'immunisation du corps humain par infections HIV
ES2129022T3 (es) Proteina condromodulina-i.
RU93034376A (ru) Лекарственное средство, стимулирующее эритроидный и гранулоцитарный ростки кроветворения при цитостатических миелодепрессиях
MX9800686A (es) Nueva proteina hmw humana mp52s.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired